# Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

Study · id `cardio:ct-nct01278160` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01278160](<https://clinicaltrials.gov/study/NCT01278160>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01278160

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 179 participants.

## Technical summary

Registry record NCT01278160. Randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2012-10-18.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 179 participants (enrolled count; ClinicalTrials.gov record NCT01278160, source copy `cardio:ctgov-nct01278160-2014-10-27`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01278160, source copy `cardio:ctgov-nct01278160-2014-10-27`, retrieved 2026-10-26)
- Primary completion: 2011-09 (actual) (ClinicalTrials.gov record NCT01278160, source copy `cardio:ctgov-nct01278160-2014-10-27`, retrieved 2026-10-26)
- Completion: 2011-09 (actual) (ClinicalTrials.gov record NCT01278160, source copy `cardio:ctgov-nct01278160-2014-10-27`, retrieved 2026-10-26)
- Results first posted: 2012-10-18 (ClinicalTrials.gov record NCT01278160, source copy `cardio:ctgov-nct01278160-2014-10-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01278160, source copy `cardio:ctgov-nct01278160-2014-10-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01278160-2014-10-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): biphasic insulin aspart 30
- Intervention (Drug): biphasic insulin aspart 30
- Intervention (Drug): metformin
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: e67d0338432a345a7fea998f91b539772045c60c4aba892746b6d1c95c5bd517
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
